Clinical Trial Update: Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating regorafenib in advanced or metastatic neuroendocrine tumors has been completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrinoma
• Gastrointestinal Carcinoid Tumor
• Glucagonoma
• Insulinoma
• Islet Cell Carcinoma
• Pancreatic Polypeptide Tumor
• Pulmonary Carcinoid Tumor
• Somatostatinoma

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: University of Southern California | Conditions: Gastrinoma, Glucagonoma | Phase 2 | Status: COMPLETED | Results posted: 2021-12-15